Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure

Annals of Transplantation

Volumn 15, Issue 4, 2010, Pages 61-67

  Basak, Grzegorz Wladyslaw ^a   Urbanowska, Elzbieta ^a   Boguradzki, Piotr ^a   Torosian, Tigran ^a   Halaburda, Kazimierz ^a   Wiktor Jedrzejczak, Wieslaw ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

AMD3100; Lymphoma; Plerixafor; Stem cell mobilization

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; B CELL LYMPHOMA; CELL COUNT; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; LEUKOCYTOSIS; MALE; MULTIPLE CYCLE TREATMENT; POEMS SYNDROME; REMISSION; STEM CELL MOBILIZATION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CXCR3; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651233917     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gratwohl A, Baldomero H, Schmid O et al: Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant, 2005; 36(7): 575-590
2. Bensinger W, DiPersio JF, McCarty JM: Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant, 2009; 43(3): 181-195
3. Richman CM, Weiner RS, Yankee RA: Increase in circulating stem cells following chemotherapy in man. Blood, 1976; 47(6): 1031-1039
4. Fu S, Liesveld J: Mobilization of hematopoietic stem cells. Blood Rev, 2000; 14(4): 205-218
5. Pusic I, Jiang SY, Landua S et al: Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant, 2008; 14(9): 1045-1056
6. Villalon L, Odriozola J, Larana JG et al: Autologous peripheral blood progenitor cell transplantation with <2×10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment. Hematol J, 2000; 1(6): 374-381
7. DiPersio JF, Micallef IN, Stiff PJ et al: Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony- stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol, 2009; 27(28): 4767-4773
8. DiPersio JF, Stadtmauer EA, Nademanee A et al: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 2009; 113(23): 5720-5726
9. Stiff P, Micallef I, McCarthy P et al: Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant, 2009; 15(2): 249-256
10. Fruehauf S, Ehninger G, Hubel K et al: Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant, 2010; 45(2): 269-275
11. Calandra G, McCarty J, McGuirk J et al: AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin;s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant, 2008; 41(4): 331-338
12. Dugan MJ, Maziarz RT, Bensinger WI et al: Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin;s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant, 2010; 45(1): 39-47
13. Moskowitz CH, Bertino JR, Glassman JR et al: Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor- cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol, 1999; 17(12): 3776-3785
14. Cancelas JA, Hernandez-Jodra M, Zamora C et al: Circulating stem cell collection in lymphoma and myeloma after mobilization with cyclophosphamide and granulocyte colony-stimulating factor for autologous transplantation. Vox Sang, 1994; 67(4): 362-367
15. Cioch M, Manko J: Autologous hematopoietic stem cell transplantation followed by thalidomide therapy in poems syndrome. Ann Transplant, 2009; 14(Suppl.1): 74-75
16. Basak GW, Urbanowska E, Witkowska M et al: CXCR4 inhibitor plerixafor and G-CSF allow for an effective peripheral blood stem cell collection in patients who failed previous mobilization attempt. Translational Biomedicine, 2010, 1(1:2).
17. D'Addio A, Curti A, Worel N et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2010; [advance online publication 31 May 2010; doi: 10.1038/ bmt.2010.128]